FDA seeks comments on ways to facilitate appropriate opioid prescribing
The Food and Drug Administration seeks stakeholder input on how it might use Risk Evaluation and Mitigation Strategies to facilitate appropriate prescribing of opioid pain relievers. For example, the agency’s Opioid Policy Steering Committee is considering using REMS to require sponsors to ensure that opioid analgesic prescriptions exceeding a certain amount document medical necessity and/or leverage a nationwide prescription history database to prevent misuse or abuse, the FDA notice states. The agency will hold a Jan. 30 public hearing on the issue, with comments accepted through March 16.
Related News Articles
Headline
A 60-day appeal window has passed for the Food and Drug Administration to appeal a federal court ruling that invalidated its final rule to regulate laboratory-…
Headline
The AHA June 3 launched the first in a new video series, “Medicaid: Real Lives, Real Care,” highlighting the importance of Medicaid and why proposed cuts…
Headline
The Department of Health and Human Services and Centers for Medicare & Medicaid Services said June 3 they are rescinding 2022 CMS guidance with the subject…
Headline
A JAMA study published June 3 found that of 2,237 counties across the U.S., 78% reported declines in vaccination rates for measles, mumps and rubella from 2019…
Headline
The AHA Leadership Summit will be held July 20-22 in Nashville, Tenn. AHA Executive Vice President Michelle Hood previews the conference designed to equip…
Blog
The 2025 AHA Leadership Summit will take place July 20-22 at the Music City Center in Nashville, Tenn. Renowned speakers from across health care will provide…